
via EYES on EYES OPTICAL
This eye disease often leads to blindness — which might be prevented by early intervention
The team headed by Dr. Jacqueline Reinhard and Prof. Dr. Andreas Faissner from the Department of Cell Morphology and Molecular Neurobiology in Bochum, together with colleagues from the University Eye Clinic in Bochum, RWTH Aachen University, the University of Toronto and the University of Denver, has published a report on their findings. The article was released on 12 October 2018 in the online edition of the journal Molecular Neurobiology.
Specific and early intervention
The researchers bred mice in which the gene PTP-Meg2 (protein tyrosine phosphatase megakaryocyte 2) was mutated . As a result, the animals suffered from chronic intraocular pressure elevation. The team successfully demonstrated that, in their model, the intraocular pressure elevation was associated with a loss of optic nerve fibres and retinal cells. Using functional analyses, they observed that retinal cells were unable to function properly, either. Moreover, they made the following discovery: glial cells and certain components of the immune system showed a reaction in the animals’ optic nerve and retina. As both aspects may be relevant for neurodegeneration, specific and early intervention into these cellular mechanisms may inhibit glaucoma.
Testing new therapy options
Making use of a genetic screening, the researchers subsequently identified new potential biomarkers. In future, these biomarkers may facilitate early detection of glaucoma; as a result, it will be possible to start therapy at an early stage, before the optic nerve and retina are damaged. The glaucoma-mouse model may, moreover, be used to test new therapy options. Experiments to date have shown that intraocular pressure was reduced and nerve cells were retained in the mice if they were given a drug that had been administered to treat human patients.
Learn more: Biomarkers facilitate early detection of glaucoma
The Latest on: Glaucoma
[google_news title=”” keyword=”glaucoma” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Glaucoma
- Hazy side vision, nausea and eye pain: Common glaucoma myths and treatment optionson September 27, 2023 at 1:00 pm
The eye's front chamber is assessed with a microscope called a slit lamp biomicroscope and a contact lens called gonioscopy, to see if there is blockage of the eye's drainage system, which can lead to ...
- Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trialon September 27, 2023 at 4:11 am
This active pharmaceutical ingredient, currently designated as a Schedule 1 controlled substance, is being developed by Skye to lower intraocular pressure ("IOP") associated with glaucoma and ocular ...
- Digital Healthcare Startup eyecbetter Launches Regulation C Crowdfunding Campaign on StartEngine.on September 26, 2023 at 9:17 am
Renowned Glaucoma Specialist Dr. Joel Solano Connects Glaucoma Patients with Innovative Digital Health Solutions that Help Prevent Blindness and ...
- Aerie Pharma Falls on Glaucoma Eye Drop Safety Concernson September 25, 2023 at 5:00 pm
Aerie Pharmaceuticals - Get Free Report disclosed new details Thursday about the safety and tolerability of its experimental glaucoma eye drop Rhopressa. The data spooked investors, sending Aerie ...
- Rising Glaucoma Cases Forecast a Strong Optic Nerves Disorder Treatment Marketon September 25, 2023 at 5:08 am
The "Optic Nerves Disorder Treatment Market by Treatment Type, Indication, Distribution Channel, and Geography: Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering. Optic ...
- An Alzheimer's-glaucoma connection? Studies differ, calling for more active researchon September 25, 2023 at 3:00 am
Like glaucoma, Alzheimer's is a neurodegenerative disease characterized by specific changes in the brain. Both of these conditions affect the majority of older populations and involve selective loss ...
- Glaucoma Therapeutics Market 2023 Is Set to Fly Excessive Growth in Years to Comeon September 21, 2023 at 11:53 pm
Glaucoma Therapeutics market focuses on analyzing the current competitive situation in the Glaucoma Therapeutics market and provides basic information, market data, product introductions ...
- U of T researchers build online glaucoma simulatoron September 21, 2023 at 11:39 am
Wong and Li’s online simulator is based on a data-driven model they developed to help quantify glaucoma measurements. Their model, which takes into consideration the physiological mechanism of the eye ...
- Glaucoma Therapeutics Market: Future Growing Trends and Forecast from 2023 to 2030on September 21, 2023 at 10:32 am
The global Glaucoma Therapeutics market size was valued at USD 7410.9 million in 2022 and is expected to expand at a CAGR of 6.16 Percentage during the forecast period, reaching USD 10611.0 ...
via Bing News